Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Europe's largest pharmaceutical firm, Novo Nordisk, revealed positive trial results for its next-generation obesity drug, amycretin, marking a major step in its ... of 24.4% over 48 weeks.

LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial ...

Semaglutide 2.4 mg is marketed under the brand name Wegovy. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will ...

In the Phase IIIb STEP UP trial, 7.2mg Wegovy demonstrated statistically significant ... which resulted in losses of 17.5% and 2.4%, respectively. In addition, 33.2% of subjects receiving the ...

Citing topline data from its STEP-UP Phase 3b study, the Danish drugmaker said that while patients on regular Wegovy at 2. ... placebo experienced 2.4% weight loss. The trial involving more than ...

Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy ... Step Up trial was conducted to test the efficacy of the higher dose, as the current highest dose available is 2.4 ...

In the phase 3b STEP UP study ... compared to placebo or semaglutide 2.4 mg, which is currently the highest dose of the drug marketed under the Wegovy brand for obesity. Digging into the data ...